1.2 Billion Valuation Targets a Shortage of Military Working Dogs

American military and law enforcement units are facing a growing dependency on foreign bred working dogs, a gap that new venture Warhound intends to close. The company, which emerged from stealth on Thursday, has secured 200 million dollars in funding to develop genetically engineered canines for hazardous missions. This fresh capital values the startup at 1.2 billion dollars and comes from a group of investors that includes Sequoia, 8VC, Corner Ventures, and In-Q-Tel, a venture firm with ties to U.S. intelligence agencies. The immediate implication for service members is a potential shift in the supply chain for critical assets currently imported from Europe.

The urgency behind this venture stems from a strained domestic supply. According to Warhound, more than 80% of the U.S. military’s working dogs are sourced from Europe. Furthermore, fewer than half of those imported animals are deemed fit for service upon arrival. This creates a logistical vulnerability where the nation relies heavily on foreign breeding programs for dogs that perform bomb detection, searches, and other high risk operations. The new company seeks to engineer a domestic solution that is better suited to the specific demands of American tactical environments.

The concept was born from a collaboration between Ben Lamm of Colossal Biosciences and Palmer Luckey, the founder of Anduril. Lamm noted that he and Luckey first connected about a year ago at a conference, where the topic of improving military working dogs was raised. Following that meeting, Lamm investigated the breeding practices of current working dog lines. He discovered that many dogs fail training due to inherited genetic issues, including poor eyesight, high cancer risks, hip dysplasia, and muscle atrophy. These biological limitations often reduce the effective lifespan and utility of the animals in the field.

Warhound’s approach involves using biotechnology to create a new type of dog. The team has established a biobank using cell lines from top performing breeds, specifically Belgian Malinois and German Shepherds. Scientists will edit the genetic material to remove traits associated with these common health issues and add characteristics that enhance speed, agility, and olfactory sensitivity. The goal is to produce animals with improved longevity and physical performance, making them more resilient during demanding missions.

Beyond genetics, the dogs will be equipped with hardware and software provided by Anduril. This technology is designed to improve situational awareness for both the canine and its handler. Lamm described the concept as adding protective gear, such as bulletproof vests with data sensors, that transmit real time information back to the handler. This setup allows for better coordination and safety, ensuring that the human operator has a clearer understanding of the operational environment. The technology is described as an external enhancement that works in tandem with the internal genetic improvements.

The path to deployment is already in motion. Lamm stated that the first batch of dogs is about to be cloned and incubated. Viagen, a company owned by Colossal, will handle the cloning process using a technology that boasts a high success rate. Births are expected early next year, with the first dogs entering service within two years. Colossal will support the venture by licensing its genetic technology, while Luckey is a partner in the business but holds no equity. The company has not yet determined pricing but expects to sell to first responders, the Department of Defense, and police forces.

Welfare and regulatory oversight are central to the launch. Warhound is working under the guidance of the American Humane Society to certify its training program. The organization aims to ensure that the new dogs are treated with scientific and ethical rigor. The American Humane Society stated that it is pleased to be involved, noting that it looks forward to ensuring the animals are treated humanely. Additionally, the company hopes that when these dogs retire, they can enter the Society’s Military Working Dog Reunification Program to find permanent homes.

Looking ahead, the company has briefed various government groups on its plans, though specific approval timelines were not detailed. Lamm emphasized that each dog will undergo standard training and be managed by the purchasing agency. The success of this 200 million dollar venture will depend on whether the engineered dogs can reliably outperform traditional imports in both health and operational capability.

The next two years will be critical as the first clones are born and tested. If the timeline holds, American handlers could begin using these new canines by late 2028. This shift represents a significant change in how the U.S. procures biological assets for defense, moving from a model of importation to one of domestic engineering and technological integration.